Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

UNCOVERED: 64 - Caught on Camera

GlaxoSmithKline says it will not start any new clinical trials in Russia

Pharma firm joins AstraZeneca and Pfizer in saying it will not enrol new patients into studies

The Guardian - UK

Ionis Pharma Announces Publication Of Positive Donidalorsen Data For Angioedema Attacks

Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced the publication of Phase 2 data for donidalorsen in the New England Journal of Medicine (NEJM). Donidalorsen is an investigational antisense medicine under development for hereditary angioedema (HAE), a disorder characterized by recurrent episodes of severe swelling. In the Phase 2 study, donidalorsen demonstrated a 90% reduction in…

Benzinga

COVID boosters' short effectiveness window brings skepticism about 4th shot

Some experts are already skeptical that another shot is warranted for most people.

Axios

From analysis to the latest developments in health,
read the most diverse news in one place.

Second COVID-19 booster shot does little to stop omicron, study finds

Israeli health care workers who were boosted with a fourth shot of COVID-19 vaccine at the height of the omicron wave were only marginally more protected against reinfection than their peers who had received three jabs of vaccine, researchers reported Wednesday.

Los Angeles Times

What Are Whales Doing With Pfizer

A whale with a lot of money to spend has taken a noticeably bullish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 17 strange trades.

Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study

Here's a roundup of top developments in the biotech space over the last 24 hours.

Benzinga

Pfizer-BioNTech Seek US Approval of Second Covid Booster for 65+

Pfizer and BioNTech announced Tuesday they had formally asked the United States drug regulator for emergency approval of a second booster shot of their Covid vaccine for people aged 65 and older. The companies said in a press statement that their request is based off two Israeli studies that show…

Asharq Al-Awsat

Read news from The Economist, FT, and more,
with one subscription

Pfizer asks FDA to clear another booster for older adults

Pfizer Inc. said it has asked U.S. regulators for clearance of an additional COVID-19 booster shot for seniors, in a bid to protect vulnerable adults as immunity provided by the first three doses wanes.

Tribune News Service

The Loop: Another Pfizer booster on table in US, hospital hostages in beseiged Mariupol, and a Grammys showstopper

Here's your TL;DR for this morning's news.

ABC News

AP source: Pfizer seeking OK for 4th COVID dose for seniors

Drugmaker Pfizer is expected to request authorization this week for an additional COVID-19 booster dose for seniors

The Independent UK

Pfizer and BioNTech plan to seek authorization for second COVID booster for people 65 and up

The move is an attempt to bolster waning immunity that occurs several months after a first booster shot.

Axios

News briefs

Fourth COVID shot will be ‘necessary,’ says Pfizer CEO

Tribune News Service

Pfizer halts trials in Russia but will continue to supply drugs

Pfizer Inc. said it would no longer start new clinical trials in Russia and that it would donate all profits from its subsidiary in the country to Ukraine relief causes.

Tribune News Service

Pfizer CEO says fourth vaccine dose will be needed

CDC only authorised third jab for most adults in the fall

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Pfizer To Stop New Clinical Trials In Russia: Reuters

Reuters reported that Pfizer Inc (NYSE: PFE) said it wo

Benzinga

Here's Why Pfizer And Novavax Shares Are Rising On Monday

Pfizer Inc. (NYSE: PFE) and Novavax, Inc. (NASDAQ: NVAX) shares are trading higher by 4.3% at $52.42 and 9.6% at $80.05 respectively. Strength is possibly due to a spike in COVID-19 cases in China, which could lift vaccine sector sentiment.

Benzinga

Pfizer-BioNTech's COVID-19 Shot Moderately Effective Against Omicron In Kids Aged 5 to 15, CDC Study Shows

The Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX) vaccine is only moderately effective against the omicron variant when tested in children ages 5 to 15.

Tribune News Service

Fourth COVID shot will be ‘necessary,’ says Pfizer CEO

COVID-19 shots could soon become an annual item on your to-do list.

Get all your
news in one place.

100's of premium titles.
One news app.

Caixin Global

Pfizer’s Covid-19 Drug Arrives in Hong Kong, City’s Leader Says

The first batch of 75 Chinese mainland medical personnel has also arrived in Hong Kong to boost the city’s capacity to treat severe cases amid the worst local outbreak

Reuters

Pfizer, Bayer to maintain drug supply to Russia

Pfizer Inc and Bayer said on Monday they would maintain humanitarian supply of medicines to Russia, but would pull back from other non-essential spending in the country.

Wales Online

Pfizer vaccine reduces Covid infections in children, research finds

It also reduces the severity for those that do catch the virus

The Independent UK

Covid-19 vaccine ‘reduces infections in children’ – study

It is expected that five to 11-year-olds in England will be called forward for vaccines in April.

The Conversation

Two years into the pandemic, unequal access to COVID-19 treatments threatens the global recovery

It’s now two years since the World Health Organization began calling the COVID-19 outbreak a pandemic.

Caixin Global

Weekly Must-Read: China Meheco Confirms Pfizer Talks on Selling Paxlovid in China

State-owned drugmaker’s shares surge by 10% limit on four straight days in Shanghai, though its role may be limited to distribution logistics

Tribune News Service

Which companies aren’t exiting Russia? Big pharma

Even as the war in Ukraine has prompted an exodus of international companies — from fast-food chains and oil producers to luxury retailers — from Russia, U.S. and global drug companies said they would continue manufacturing and selling their products there.

1 … 63 64 65 66

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

New England Journal of Medicine

31 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.